Economic evaluation of community acquired pneumonia management strategies: A systematic review of literature

Marufa Sultana, Abdur Razzaque Sarker, Nausad Ali, Raisul Akram, Lisa Gold

Nutrition and Clinical Services Division, International Centre for Diarrheal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh, Deakin Health Economics, School of Health and Social Development, Deakin University, Geelong, Victoria, Australia, Health Economics and Financing Research, Bangladesh Institute of Development Studies (BIDS), Dhaka, Bangladesh, Health Systems and Population Studies Division, International Centre for Diarrheal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh

* marufa@icddrb.org

Abstract

Background

Community-acquired pneumonia (CAP) is a major cause of mortality and morbidity worldwide. Efficient use of resources is fundamental for best use of money among the available and novel treatment options for the management of pneumonia. The objective of this study was to systematically review the economic analysis of management strategies of pneumonia.

Methods

A systematic search was performed using Academic Search Complete, MEDLINE, EconLit, Global health, MEDLINE complete and Embase databases using specific subject headings or key words in May 2018 without restricting publication year. All search results were recorded and any type of economic evaluation for management of CAP was included for detailed review. The Consolidated Health Economic Evaluation Reporting Standards (CHEERS) checklist was used for quality appraisal.

Results

Nineteen studies met the inclusion criteria; ten studies were trial based, five conducted analysis using model based techniques and the rest of the studies were either based on observational, record review or pre-post intervention studies. Most of the studies conducted cost-effectiveness analysis (n = 15) and compared different combinations of antimicrobials. Most were based on developed countries (n = 17), considered adult age groups (n = 16) and used a provider perspective (n = 14). Nine studies reported dominant alternatives (lower cost with higher benefit). Sensitivity analysis was performed by the majority of studies (n = 15). Fourteen studies were assessed as either being excellent, very good or good quality, with no relationship found between publication year and study quality. Methodological variation, type of microbial used, perspective, costs and outcome measures limit the compatibility among the results of the included studies.

Editor: Yuri Tertius Jadotte, Stony Brook University, UNITED STATES
Received: May 3, 2019
Accepted: October 6, 2019
Published: October 24, 2019
Copyright: © 2019 Sultana et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability Statement: All relevant data are within the manuscript and its Supporting Information files.
Funding: The authors received no specific funding for this work.
Competing interests: The authors have declared that no competing interests exist.
Conclusion
Economic evaluation of interventions for management of CAP to date supports cost-effectiveness of studied interventions. However, evidence relates largely to antimicrobials choice in older populations in developed countries. Parallel economic evaluation of different management strategies of CAP is recommended for both developed and developing countries to support rigorous and robust comparative economic analysis within health care systems.

PROSPERO registration no: CRD42018097174

Introduction
Community-acquired pneumonia (CAP) is a major cause of morbidity and mortality worldwide and is associated with excessive health care consumption and cost [1,2]. Suspected CAP is defined as “acute symptoms and presence of signs of lower respiratory tract infection (LRTI) without other obvious cause, whereas new pulmonary infiltrate on chest radiograph is needed for definite diagnosis” [1]. Despite noticeable improvement in the management of CAP, it still remains as a health burden for both developed and developing countries [3,4]. The 2013 Global Burden of Disease (GBD) study estimated that lower respiratory infection (LRTI) particularly pneumonia remains the second leading contributor of global disability-adjusted life years (DALYs), and accounted for approximately 1,400 age-standardized DALYs per 100,000 population [4]. CAP remains as a leading cause of death for infectious diseases in the United States and Canada [3]. Incidence rates of CAP range from 1.6–11.6 per 1000 in Europe [5]. The incidence rates reported in the Asia-Pacific region have ranged from 0.2–0.9 per 1000 [6], although these may be underestimated [5]. Incidence of CAP by age follows a U-shaped pattern, with the highest incidence amongst under-five years and over 60 years age groups [7]. Depending on clinical presentation, pneumonia is classified as pneumonia, severe pneumonia, or very severe disease according to the 2013 WHO guidelines [8].

Pneumococcal vaccine (PCV) and Haemophilus influenzae type b (Hib) conjugate vaccines have been incorporated in many countries as a preventive strategy for pneumonia [9,10]. Since vaccine efficacy varies and pneumonia is caused by different types of pathogens, cost-effective management strategies are also deemed important to tackle the morbidity and mortality caused by pneumonia. Standard management of pneumonia usually relies on hospital management including oxygen therapy, antibiotics, and careful monitoring [8,11]. A study in the Netherlands found that, among 0.12 million cases of CAP between 2008 and 2011, 63% of cases required hospitalization, with a mean 6.7 days length of hospital stay [7].

Management of pneumonia is associated with significant economic burden, especially for inpatient hospital care [12–15]. The burden is particularly concerning in low-income countries, where a high economic and health burden for governments and households is often combined with limited access to health care facilities and low quality of services provided [4,10]. With limited resources and growing healthcare needs, economic evaluations have become important tools to help policy makers allocating scarce resources efficiently [16–19]. Decision makers require information regarding the effect of interventions or programs in terms of their costs and associated benefits [18]. Therefore, economic evaluation is crucial to identify the treatment options with best value for money through systematic analysis of costs against associated outcomes [19,20]. This evaluation is particularly imperative for low-income setting with high burden of infectious diseases.
Economic evaluation of different interventions of CAP management has been conducted from various perspectives, however, high quality of reporting also needs to be ensured in order to generate evidence with validated results and to inform policy. To our knowledge, there is no systematic review focused on economic evaluation of CAP management strategies. As such, the aim of this study was to conduct a systematic review of economic evaluation of the management of CAP and to provide a comprehensive summary of the economic evidence to date.

Methods

Search strategy

A systematic literature search was conducted in electronic databases using indexed subject headings and free text from early-mid May 2018 to identify published articles that provided cost as well as outcome data of pneumonia management. Academic search complete, MEDLINE, EconLit, Global health and MEDLINE complete databases were searched through the EBSCOhost database. Further, a separate search was also conducted through the Embase database. The search strategy used thesaurus and EMTREE as subject headings for EBSCOhost and Embase databases respectively (Supplementary 1). Methods were based on other systematic review studies in the area of economic evaluation and results are reported following PRISMA statement guidelines [21]. The systematic review protocol was registered prior to conduct of the review (PROSPERO Registration Number: CRD42018097174). Available at: http://www.crd.york.ac.uk/PROSPERO/display_record.php?ID=CRD42018097174

Inclusion and exclusion criterion

All peer reviewed full-text articles available in English that included any type of economic evaluation for management of pneumonia were included in the review. Studies were included in the review when they fulfilled all of the following inclusion criteria:

- Economic evaluation that reported costs and outcomes of at least two alternatives
- Any type of economic evaluation (i.e., cost-minimization analysis [CMA], cost-effectiveness analysis [CEA], cost-utility analysis [CUA], cost-benefit analysis [CBA])
- Clinical management of CAP
- Published in any year
- Based on studies done alongside randomized clinical trials (RCTs) or observational studies, or modelling studies. Full text journal articles
- Published in English or other languages if English version available

Studies were excluded from the review when they met any of the following exclusion criteria:

- Partial economic evaluation, i.e. with no comparison group, or only cost analysis of management of pneumonia
- Only clinical outcome/effectiveness or benefit using non-monetary terms (no costs)
- Economic evaluation other than treatment of pneumonia (for example, preventive intervention for pneumonia such as vaccination)
- Books, reports, reviews, letters, editorials, perspectives, abstracts, and methodological articles
Selection process

Search results were initially screened against inclusion/exclusion criteria on the basis of the title, abstract and publication details. Studies that were not relevant to pneumonia management or cost-effectiveness; and conference, editorial, commentary and review studies were excluded at this stage. Different types of economic evaluation studies that focused on vaccination for preventing pneumonia were also excluded. Screening was undertaken by three researchers independently (MS, RA, NA) and a study was excluded on title and abstract only if all reviewers agreed. Any disagreements were resolved by evaluating the full-text of the paper (MS, ARS, RA, NA). Full text of potential studies for inclusion were obtained and assessed against inclusion criteria.

Data extraction and synthesis

For each of the included studies, data were independently extracted by two reviewers (MS and LG) using a formatted spreadsheet in Microsoft Excel. Data extraction followed guidance of ‘Cochrane Handbook’ chapter on economic evidence [22]. As such, following data were extracted regarding the characteristics of each economic study: study year and study period, detail of intervention and comparators, study design and source(s) of resource use, study population, study location/country and setting, unit costs of resources used with currency and price year, type of economic evaluation, time horizon of both costs and effects, analytical viewpoint, effectiveness data, sensitivity analysis, decision-making statements, and limitations. For results, resources used and unit costs estimates associated with interventions and comparators were extracted separately. Outcome data such as LOS in days, follow-up periods, patients and caregivers’ time were extracted as natural units [22]. Meta-analysis was not conducted in this review. Resource use and outcome data were not pooled since outcomes were different across RCTs and other studies. In addition, a range of methodological variations, country specific results, differences between health systems and study perspective restricted quantitative comparability across studies. Therefore, a qualitative narrative i.e. comprehensive synthesis that focused on critical appraisal and discussion of the major findings of was of included studies was employed. All the costs identified within included studies were converted to 2018 US dollars (US$) to increase compatibility of the results [22]. To accomplish this, cost data were converted to international dollar units (US dollar value) using EPPI-CCEMG Cost calculator (https://eppi.ioe.ac.uk/costconversion/). As per earlier study, cost data were set to one year prior to publication year to convert if year was not stated [17]. The study characteristics are summarized in tables and figures.

Quality (risk of bias) assessment

The quality of included studies was evaluated against 24 key criteria specified in the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) checklist [23]. This recently-published checklist, consisting of 24-item, was supported by the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), BMJ and other publications [23]. This checklist includes six major areas: title and abstract (two items); (ii) introduction (one item); (iii) methods (14 items); (iv) results (four items); (v) discussion (one item); and (vi) other, which is related to funding and conflict of interest (two items) those need to be reported in economic evaluation studies [23].

A score was given for each applicable item and a total score (out of 24) was obtained for each study. Studies that fully met each of the items of the checklist were scored as ‘1’, those deemed to have partially met each of the criteria were scored as ‘0.5’ and scored ‘0’ if studies did not meet the criterion at all [19]. Therefore, total score was obtained ranging from 0 to 24
points. Two reviewers (MS and LG) discussed the ratings before final calculation of the score. Based on earlier studies, studies were considered as “excellent quality” of reporting with a score higher than 85%, 70–84% as “very good quality”, 55–69% as “good quality” while studies with lower than 55% were considered as “poor quality” [19,24].

**Results**

**Search results**

Fig 1 describes the search results and selection process. The initial searches through EBSCO-Host and Embase databases yielded 3,363 and 2,167 titles and abstracts respectively. Duplicates were removed from the identified articles. Publications clearly not meeting inclusion criteria were excluded on screening of title and abstracts (n = 3,147). A further 26 papers were excluded after reviewing the full text. Finally, nineteen peer-reviewed eligible articles were included for detailed review.

![Flow chart of literature search (PRISMA) for economic evaluation studies.](https://doi.org/10.1371/journal.pone.0224170.g001)
Characteristics of the selected studies

The characteristics of the included articles are summarized in Table 1. Most studies performed cost-effectiveness analysis (n = 15) and were conducted in developed countries (n = 17) i.e. United States (n = 7), Germany (n = 4) or other European countries (n = 6). Only two studies were conducted in a low and middle income country context (Malawi and Malaysia) [25,26]. Studies were mainly conducted from a hospital/government, health system, or third party perspective (n = 14), while two studies reported a broader societal perspective [27,28]. Ten studies were based on randomized controlled trials, five studies were model based and the remaining 4 studies were either observational or pre-post intervention analysis. The sample size of included studies ranged from 28 to 2,283 (median 337). Most studies considered adults (n = 15; mean age ranged from 48–72 years); two studies were based on under-five children [25,26] and one study considered all age groups [29]. Publication years ranged from 1998 to 2017, with 84% (n = 16) of the studies published before the publication of the CHEERs checklist in 2013.

Most studies compared the efficacy of different combination of antibiotics, ranging from 1st-3rd generation antibiotics (penicillin, gentamycin, cephalosporine, fluoroquinolone, macrolides, carbapenem, B-lactum etc.), with associated costs (n = 12). Two studies evaluated other

Table 1. Summary of study characteristics.

| Study Characteristics                  | No of studies | Study design |
|----------------------------------------|---------------|--------------|
| **Type of Economic evaluation**        |               | RCT | Model | Pre-post/others |
| CMA                                    | 3             | 2   | 0     | 1               |
| CEA                                    | 15            | 8   | 4     | 3               |
| CUA                                    | 1             | 0   | 1     | 0               |
| **Perspective**                        |               |     |       |                 |
| Societal                               | 2             | 2   | 0     | 0               |
| Hospital/government                    | 9             | 5   | 1     | 3               |
| Health system/third party payer        | 5             | 1   | 3     | 1               |
| Not specified                          | 3             | 2   | 0     | 1               |
| **Population**                         |               |     |       |                 |
| All age groups                         | 1             | 0   | 1     | 0               |
| <5 years                               | 2             | 1   | 1     | 0               |
| ≥5 years                               | 15            | 9   | 3     | 3               |
| Not specified                          | 1             | 0   | 0     | 0               |
| **Main treatment method evaluated**    |               |     |       |                 |
| Staff education with antibiotics       | 1             | 0   | 0     | 1               |
| Single or combined doses of oral/IV antibiotics | 17       | 9   | 5     | 3               |
| BCPAP with antibiotics                 | 1             | 1   | 0     | 0               |
| **Comparison group**                   |               |     |       |                 |
| Existing practice                      | 2             | 1   | 1     | 0               |
| Another specific treatment group       | 12            | 9   | 0     | 3               |
| No intervention                        | 5             | 0   | 5     | 0               |
| **Year of publication**                |               |     |       |                 |
| 1998–2012                              | 16            | 9   | 3     | 4               |
| 2013–2018                              | 3             | 1   | 2     | 0               |
| **Country according to income level**  |               |     |       |                 |
| High income countries                  | 17            | 9   | 4     | 4               |
| Low and middle income countries        | 2             | 1   | 1     | 0               |

https://doi.org/10.1371/journal.pone.0224170.t001
interventions along with recommended antibiotics; one described usual management of pneumonia with an intervention that combined staff education, visual reminder and manual [30] and the other compared usual care with the bubble continuous positive airway pressure (bCPAP) alongside other supportive care [26] (Table 2).

**Reported cost of the studies**

Reported costs were mainly based on the chosen perspective and the nature of the study (trial or model based). All studies reported direct costs of the treatment, with most commonly reported costs related to antimicrobial drug costs (including preparation, dispensing and administrative costs). In general, direct costs also included hospital per diem/stay costs, physician costs, costs of other drugs, laboratory tests, and staff training costs. Cost of side effects was considered by three studies [31–33]. The two studies reporting a societal-perspective analysis estimated loss of productivity (days out of role), home care and out-of-hospital resource use costs (tests, X-rays and drugs) [27,28]. Only van Werkhoven et al. included non-health care costs (travel cost) in cost analysis [28]. Detailed methodology of cost analysis was not described by two studies [30,34]. Unit costs were mainly sourced from local tariffs, medical records, experts’ opinion and published literature. Multi-country trials presented cost data in a single currency [35–37]. Currency was reported in all studies, however, reporting year was not specified by four studies [26,32,34,38]. Due to the short time periods involved, most studies did not apply discounting for cost analysis (n = 17), five studies provided this justification [32,39–42]. One study applied a 3% discount rate for cost and outcome without specifying the time horizon considered, another study discounted productivity loss at a rate of 3% if it was longer than a year but no discounting for cost was applied [26,28].

It is important that an evaluation is conducted over a time horizon that includes all relevant costs and consequences from the chosen perspective of the study [22,23]. More than half of studies (n = 10) specified the time horizon/duration of the treatment, with follow-up that ranged from 21 days to lifetime. However, eight studies (42%) specified their duration of the study period only. Sensitivity analysis was performed by 78% of the studies (n = 15) and length of hospital stay (LoS) was commonly reported as the most cost-sensitive parameter.

**Summary results of effectiveness and economic evaluation**

The economic evaluation studies selected for this review were conducted in different countries and the evaluated management strategies included different combinations of antibiotics. In addition, study design, type of intervention(s) and description of the usual care also differed widely. In this narrative review, we found that Intention to treat (ITT) approach was applied by all studies, with 11 studies imputed missing data for analysis. Outcomes were mainly reported as clinical success (defined as cured or condition improved), deaths prevented, mortality averted, Quality Adjusted Life Years (QALYs) gained and DALYs averted. None of the included studies conducted cost-benefit analysis.

Trial or pre-post outcome based studies (n = 14) expressed economic evaluation outcomes as cost per patient (n = 5, 26%) [24,26,27,36,42], cost per case cured (n = 3, 16%) [31,34,36], cost per expected success (n = 4, 22%) [32,33], cost per clinical improvement (n = 1, 6%) [43], and cost per death prevented (n = 1, 6%) [30]. Comparators included different combinations of antibiotics, usual care, and intervention based on staff education. Of the studies assessing cost per patient (n = 5), three studies performed CMA [27,37,44], one conducted CEA [25] and one study combined both CMA and CEA [28]. For CMA studies, two studies reported lower costs with equivalent outcomes particularly for drugs with lower purchase costs or reduced hospital stay [27,37]. van Werkhoven et al. employed both CEA and CMA for the
### Table 2. Summary of the economic evaluation studies on management of pneumonia.

| Author (Year) | Analysis | Perspective | Country | Population, Sample size (SS) | Study design | Intervention & Comparators | Main cost measurement | Cost/outcome measure | Currency, year | Sensitivity analysis | Main results (2018 USD) | CHEERS score and quality |
|---------------|----------|--------------|---------|----------------------------|-------------|----------------------------|----------------------|----------------------|----------------|----------------------|--------------------------|---------------------------|
| van Bemingen et al. (1998) [29] | CEA | Health system | Germany | All age with CAP, SS: NS | DA model (modified delphi technique); | 3 first line antimicrobials: macrolides, fluoroquinolones, and cephalosporins | Outpatient medication, consultation, diagnostic tests, number of hospital days | cost per successfully treated patient | Euro, 1996 (German tariff) | Several parameters used from delphi panel and literature; moderate CAP is very sensitive for first line success rate due to high hospitalization costs for treatment failure | As per cost per measure MEd CAP: fluoroquinolones < macrolides < cephalosporins US $404 < US$432 < US$806 Moderate CAP: cephalosporins < fluoroquinolones < fluoroquinolones US$1,647 < US$1,713 < US$2,189 | 14 (good) |
| Dietrich et al. (1998) [31] | CEA | Hospital & insurer | Germany | >18 years with CAP including exclusion criterion, SS: 604 | Observational, multisite | Third generation cephalosporin (ceftriaxone) compared with a second-generation cephalosporin (cefotaxime) | Antimicrobials preparation, administration, dispensing and drug costs, lost side effects, diagnostic tests and other drug costs | cost per successfully treated patient | Deutsche Mark (DM) and USD, 1998 | Threshold calculated; ceftriaxone remained cost-effective with assumed changes of personnel, laboratory and other costs. | Significant difference in success rate between two antibiotic groups (81.4% vs 91%, p < 0.001). Cost lower with third generation (ceftriaxone) due to lower preparation and administration costs that led lower per patient cost (US$154 Vs US$386). | 10 (poor) |
| Caldwell et al. (1999) [34] | CEA | Hospital | USA | >18 years with severe pneumonia, SS: 27 | RCT | Ciprofloxacin compared to imipenem | Costs of antimicrobials, hospital per diem costs from hospital rates | cost per patient cured and imipenem | USD, year not specified | Not presented | Clinical resolution was 77% and 50% for Ciprofloxacin and imipenem group respectively. Cost per case cured was 2.6 times higher for imipenem (US$ 42,520 Vs US$ 111,433 for Ciprofloxacin Vs imipenem). | 8.5 (poor) |
| Rittenhouse et al. (2000) [41] | CEA | Not specified | USA | >18 years with CAP including exclusion criterion, SS: 211 | RCT | Oral levofloxacin with oral cefuroxime Axetil | Drug costs, OP/ED hospital care including tests. Unit costs from Medicare fee schedule or estimated. | Clinical improvement | USD, 1997 | Excluded one outlier for sensitivity analysis (patient recovered in 4 days); Included costs not related to pneumonia | Drug cost was lower for levofloxacin (US$216 vs US$ 264) both for base case and sensitivity analysis. Overall difference not significant (US$1,061 vs US$ 1,309). | 8 (poor) |
| Diener et al. (2001) [32] | CEA | Hospital | USA | >18 years with CAP including exclusion criterion, SS: 201 | RCT | IV fluoroquinolone (gatifloxacin) with IV cephalosporin (ceftriaxone) with or without IV erythromycin to oral clarithromycin | Antimicrobials preparation and administration, dispensing and drug costs; costs of side effects; hospital per diem costs. CAP-specific hospital per diem estimates | Mean cost per expected success | USD, not specified | Flexible ranges tested in sensitivity analysis; economic decision was not altered after sensitivity analysis employed | No significant difference found in treatment success rate between groups (97% vs 91%). Cost per outcome lower for gatifloxacin than ceftriaxone thus cost-effective (US$5,450 Vs US$ 8,227). | 13.5 (good) |
| Paladino et al. (2002) [36] | CEA | Hospital | USA | >18 years with CAP including exclusion criterion, SS: 266 | RCT | IV oral atorvastatin Vs ofloxacin without erythromycin | Antimicrobials preparation, administration, dispensing and drug costs; diagnostic tests, hospital stay costs, weighted DRG per diem | Cost effectiveness ratio per expected cure | USD, year not specified | Several key parameters used for sensitivity analysis; Costs consistently lower for atorvastatin thus economic decision unchanged. | No significant difference in treatment success (78% vs 75%). Overall cost was lower for atorvastatin (high purchase price but lowers LoS, duration of treatment and admin cost) thus cost-effective. | 13.5 (good) |

*Continued*
Table 2. (Continued)

| Author (Year) | Analysis | Perspective | Country | Population, Sample size (SS) | Study design | Intervention & Comparators | Main cost measurement | Cost/ Currency, Sensitivity analysis | Main results (2018 USD) | CHEERS score and quality |
|---------------|----------|-------------|---------|------------------------------|-------------|---------------------------|-----------------------|----------------------------------|-------------------------|--------------------------|
| Drummond et al. (2003) [30] | CEA | Health system | France and Germany | >18 years with CAP including exclusion criterion, SS: 622 | RCT | IV fluoroquinolone (moxifloxacin) Vs IV/oral co-amoxyclav with macrolide | Drug costs, hospital stay, out of hospital care (tests, X-rays & drugs) | Cost per case cured, probability of cost saving | One-way sensitivity analysis using several parameter接受ability thresholds showed moxifloxacin is cost-effective or cost-saving | 16 (very good) |
| Frei et al. (2009) [41] | CEA | Hospital | USA | >18 years with severe pneumonia, SS: 393 | case record review | 4 groups compared by first line Antimicrobial: levofloxacin, ceftriaxone, cefuroxime + macrolide, levofloxacin | Charge for hospital stay (drugs, diagnostic tests, emergency department) | Cost-effectiveness ratio | USD, 2005 Probabilistic sensitivity analysis on cost-effectiveness ratios; levofloxacin was most cost-effective | Per patient cost US$6411. Cost varied among drug groups but no significant difference. | 12 (good) |
| Hasali et al. (2005) [35] | CEA | Not specified | Malaysia | Children 2–39 months with moderate CAP, SS: 40 | RCT | IV ampicillin Vs IV/ampicillin + IV gentamycin | Drug costs, drug administration costs, lab costs, hospital stay, staff costs | Cost per patient | Malaysian Ringgit, 2005 Not presented | Per patient cost lower for ampicillin than combined (US$159 Vs 247). Less staff costs, drug costs, admin and hospital costs lower in intervention | 30.5 (poor) |
| Samsa et al. (2005) [27] | CMA | Societal | USA | >18 years with CAP including exclusion criterion, SS: 163 | RCT | IV/ oral azithromycin Vs IV/oral levofloxacin | Drug costs, hospital stay (by ward), home care, out-of-hospital HC use, productivity loss | Cost per patient | USD, 2002 100 bootstrap samples with replication; 98 exceeded per patient cost of intervention | Cost per patient higher among levofloxacin group (Azithromycin vs levofloxacin: US$12,630 vs 16,008). Difference was due to lower LoS. | 12 (good) |
| Barlow et al. (2007) [30] | CEA | Hospital | Scotland | >16 years with CAP including exclusion criterion, SS: 503 | Pre-post with intervention and control | CAP management pathway (staff education sessions, visual reminders, manuals) compared to usual care | 1st Antimicrobials dose, intervention costed mainly by staff time | Cost per death prevented | GBP, 2002 Intervention cost and scale up cost included for sensitivity analysis | Patients receiving appropriate antibiotics within 4 hours of admission increased by 17% (adjusted). Cost per additional patient was US$ 261. | 34.5 (good) |
| Bhardwaj et al. (2008) [31] | CEA | Hospital | Multinocentry (mainly North America) | >18 years with CAP without immunocompromised, SS: 341 | RCT | oral gemifloxacin Vs intravenous ceftriaxone followed by oral cefuroxime with or without a macrolide | Antimicrobials preparation, administration, dispensing and drug costs; diagnostic tests, hospital stay costs; cost of side effects | Median cost per expected success | USD, 2004 Not presented | No significant difference among clinical success (77% vs79%). Cost lower for gemifloxacin in all 1st, 2nd and 3rd level treatment. Cost per expected success lower for gemifloxacin thus cost effective (non-significant) | 11.5 (good) |

(Continued)
| Author (Year) | Analysis | Perspective | Country | Population, Sample size (SS) | Study design | Intervention & Comparators | Main cost measurement | Cost/ Currency, Sensitivity analysis | Main results (2018 USD) | CHEERS score and quality |
|--------------|----------|-------------|---------|------------------------------|-------------|---------------------------|----------------------|------------------------------------|------------------------|-----------------------------|
| Lloyd et al. (2008) [37] | CMA | Hospital and insurer | Multicountry (17 countries in Europe, Latin America and South Africa) | >18 years with CAP required hospitalization including exclusion criterion, SS: 773 | RCT | IV/oral moxifloxacin compared to IV/oral levofloxacin plus or biaxinome | Drug costs, hospital stay, in-hospital tests & procedures, readmission. per-patient expenditure | Euro, Unit costs from German 2006 CPI value | Presented including differences in costs and outcomes to generate ICER but no significant difference between two treatment groups; ICER of US$15,687 per additional patient cured for moxifloxacin. | 16 (very good) |
| Martin et al. (2008) [42] | CEA | Third party payer | Belgium | Not specified, patients with CAP, SS: NS | DA model | Comparison of 4 1st-line Rx's: fluoroquinolones (moxifloxacin), B-lactum (co-amoxiclav, ceftriaxone), macrolide (clarithromycin) | Drug costs, GP/ specialist/ED costs X-rays/hospital stay. | Euro, Unit costs from Belgium 2006 value | Both probabilistic and deterministic sensitivity analysis were carried out with multiple parameters. Moxifloxacin found as dominant | Costs per episode amounted to US$222 with moxifloxacin, US$342 with co-amoxiclav, US$297 with cefuroxime, US$325 with clarithromycin. The moxifloxacin/co-amoxiclav strategy offered lower rates of first-line clinical failures, rehospitalisations, and mortality than all comparators. | 14 (good) |
| Lee et al. (2009) [44] | CMA | Not specified | Hong Kong | >18 years with CAP including exclusion criterion, SS: 333 | case record review | 3 initial Rx's: amoxicillin-clavulanate (AC); AG-macrolide (ACM); quinolone (Q) | Drug costs, consultation costs | Mean cost per patient Hong Kong Dollar; unit costs from tariffs (2003, 2007) | Not presented | Mortality lower for ACM than ACQ. Overall cost lower in Q (US$11,118) vs AC (US$14,539) or ACM (US$16,250) but non-significant difference | 11 (poor) |
| Edwards et al. (2012) [39] | CUA | Health system | UK | Adults with severe pneumonia in critical care (mean age 68 years), SS: NS | Markov model | carbapenem (meropenem) with piperacillin/tazobactam | Drug costs, drug prep, dispensing & admin costs; hospital stay by type of ward & level of support; OP visits. | GBP, Unit costs from UK tariffs 2008 | Probabilistic sensitivity analysis was done using different parameters; meropenem dominates consistently | 4.77 vs 4.66 QALYs for intervention and control. Cost per patient estimated to US$3,445 vs $3,858; so intervention cost-effective. PSA supports meropenem (cost-saving in >90%) | 20.5 (excellent) |
| Grau et al. (2014) [46] | CEA | Health system | Spain | >65 years with severe pneumonia, SS: 1000 hypothetical cohort | DA model | Carbapenem (ertapenem) with 3rd generation cephalosporin (ceftazidime) | Drug costs, hospital stay. Difference in proportion of cost and treatment success | Euro, Unit costs from Spanish 2006 CPI value | One-way and probabilistic sensitivity analysis was done; length of stay was found as the key parameter | Clinical success 71% vs 65% for ertapenem Vs ceftazidime. Drug costs US$27.30 vs US$41.1 but overall cost US$7,634 vs US$7,903; ertapenem dominant in 59% of PSA. | 15 (very good) |

(Continued)
| Author (Year) | Analysis | Perspective | Country | Population, Sample size (SS) | Study design | Intervention & Comparators | Main cost measurement | Cost/ outcome measure | Currency, year | Sensitivity analysis | Main results (2018 USD) | CHEERS score and quality |
|--------------|----------|-------------|---------|------------------------------|-------------|-----------------------------|----------------------|----------------------|----------------|---------------------|------------------------|--------------------------|
| Korte et al. (2017) [26] | CEA | Govt. hospital | Malawi | Children aged 1 month–5 years with severe pneumonia, SS: NS | DA model | Bubble continuous positive airway pressure (bCPAP) plus supportive care compared to usual care | bCPAP costs (including training, pulse oximetry & NP suction). Hospital per diem cost. | averted DALYs, ICER | USD, year not specified (unit cost from Malawi) | A series of one-way sensitivity analysis | Cost per episode was US$155 vs US$90 for BCPAP vs usual care. DALYs calculated as 2.4 vs 7.4. Cost was -US$13/DALY averted so BCPAP is cost-effective. | 18 (very good) |
| van Werkhoven et al. (2017) [28] | CMA, CEA | Societal | Netherlands | >18 years with CAP including exclusion criterion, SS: 2,283 | RCT | Beta-lactam/ macrolide or fluoroquinolone compared to beta-lactam monotherapy | Drug costs, hospital stay & tests, out-of-hospital HC use, days out of role, patient costs (travel), carer days out of role. | Cost per patient, ICER for cost per death prevented | Euros, 2012 (Unit costs from Dutch sources) | Not presented | Non-significant difference outcomes in trial. 90-day costs were US$6,124 vs US$6,264 vs US$5,707 for comparators, but difference not significant | 15.5 (very good) |
economic analysis but found no significant differences in costs or outcomes among treatment modalities [28] (Table 2). Among the other CEA studies (n = 11), two studies found dominant results [31,32], where one intervention was both more effective and less costly [31]. Several other studies found no significant difference in outcomes, despite this, cost differences found to be significant in some studies [32] but not for others [38,40] (Table 2). (Table 2). Even though no significant differences was observed between treatment groups, nine studies showed low-cost alternatives among the included studies [28,30,33,34,36,38,40,43,44].

Model-based economic evaluations (n = 5) mostly applied a decision analytic model (n = 4) [26,29,41,42]; one used a Markov model [39]. The incremental cost-effectiveness ratio(s) (ICERs) were calculated by three studies, of which each study found one intervention strategy to be dominant due to higher effectiveness with lower cost [39,41,42]. Kortz et al. determined that bCPAP was cost-effective against current benchmarks, at an ICER of US$13 per DALY averted compared to usual care [26]. The study conducted by van Barlingen et al. modelled cost-effectiveness of three different antibiotics for management of mild and moderate CAP and highlighted the importance of first-line clinical effectiveness as the key cost driver for moderate CAP [29]. Among all included studies, one study conducted cost utility analysis and presented QALYs as a utility measurement (based on utility scores from the EuroQoL EQ-5D) [39].

Comparing model-based and trial-based studies, noticeable differences were identified in reporting results. In particular, significant differences in costs were reported by the majority of the selected model-based analysis (three out of five) compared to trial based interventions (four out of ten). Although most of the trial based interventions reported numerically lower costs with one strategy, these differences were often not statistically significant. This was not simply related to the sample size of trials: among the eight trial-based studies with sample size less than 300, three studies reported significant cost differences between intervention and comparator(s) [25,27,32].

All except one of the model based studies compared different antimicrobials. All model based studies conducted sensitivity analysis while four trial based studies did not specify sensitivity analysis. In most cases, neither type of studies specified time horizon or used discounting due to the short time treatment and follow-up periods involved. A societal perspective was considered only by trial based studies (n = 2), where one showed significant results [27,28].

Quality of reporting
The reporting quality of the 19 studies is summarized in Fig 2 and Table 3. Almost all studies appropriately described title, methods, interventions, key findings and policy relevance and partially fulfilled the detailed abstract section. Fig 2 represents the number of studies that fulfilled or partially addressed each recommendation of the CHEERS checklist. The least appropriately addressed items by studies included relevant aspects of system(s), analytic methods (e.g. no detailed methods of handling missing data, pooling or extrapolation, model validation and uncertainty), and description of sub-group analysis. Most frequent partially addressed items included abstracts (did not specify perspective in abstract), outcome measures (justification not provided), methodology (justification for effectiveness data source not stated), and choice of model (no justification). Just over half of included studies described item 23 (study funding and role of funder) and 24 (description of conflict of interest), which might not be stated due to variation in journal requirements.

Considering the scoring applied for this review, one study was found to be excellent (≥ 85% score), four studies were rated as very good reporting quality (scoring 70–84%), with the remaining studies rated as good (n = 9) or poor (n = 5) quality reporting.
Although the quality of reporting varied within any category of study, model-based analyses rated more highly (average score 68%) than studies based on trials (average score 52%) or other study types (average score 49%). There was also some pattern of quality of reporting by reported cost-effectiveness results: the two studies that reported both higher costs and improved outcomes [26,30] had an average rating of 68%, compared to studies that reported dominant results (average score 56%, score range 35–85%) or non-significant results (average score 52%, score range 33–67%).

Fig 3 shows the linear association between CHEERS score of each study and the publication date to determine any association between quality of reporting and publication years after modification of the checklist in 2013. The linear trend line shows no specific pattern related to study year and reporting quality ($R^2 = 0.001$).

**Discussion**

The intention of this review was to provide an overview of the current evidence regarding the economic evaluation of different management strategies for pneumonia. This review included 19 studies, mainly conducted in developed countries and focused on adult patients. Only two studies were conducted in LMICs [25,26]. The objective for most studies was evaluation of cost-effectiveness of different novel antibiotics from a provider or government perspective; only two studies adopted a broader societal perspective [27,28]. Most of the identified studies
| Checklist | van Barlingen et al. | Barlow et al. | Bhavnani et al. | Caldwell et al. | Dietrich et al. | Drummond et al. | Edwards et al. | Foy et al. | Green et al. | Hasali et al. | Koritz et al. | Lee et al. | Lloyd et al. | Martin et al. | Paladino et al. | Rittenhouse et al. | Samso et al. | van Werkhoven et al. | No. of Yes | No. of No | Partial |
|-----------|----------------------|---------------|-----------------|-----------------|-----------------|-----------------|----------------|-----------|-------------|---------------|---------------|-----------|--------------|--------------|-----------------|-----------------|-----------------|-----------|-----------|
| Title/Abstract/Background | | | | | | | | | | | | | | | | | | | | | |
| 1 | Identified as EE in title | Y | Y | Y | Y | Y | Y | Y | N | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | 18 | 1 | 0 |
| 2 | Abstract includes aim, perspective, methods, results, and conclusions | P | Y | P | P | Y | P | P | P | P | P | Y | Y | Y | Y | P | Y | Y | P | Y | 8 | 0 | 11 |
| 3 | Study Q & policy maker stated | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | 19 | 0 | 0 |
| Methods | | | | | | | | | | | | | | | | | | | | | |
| 4 | Study population & sub-groups described, with why sub-gps chosen | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | N | Y | P | P | P | 15 | 1 | 3 |
| 5 | Relevant aspects of system(s) stated | Y | Y | N | N | N | N | N | N | N | N | N | N | N | N | N | N | 2 | 17 | 0 |
| 6 | Perspective stated & related to costs included | Y | Y | Y | N | Y | Y | Y | Y | N | Y | P | Y | Y | Y | N | Y | Y | 15 | 3 | 1 |
| 7 | Interventions described & choice explained | P | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | 16 | 0 | 1 |
| 8 | Time horizon stated & justified | N | Y | N | N | N | N | N | Y | Y | N | Y | Y | N | P | N | N | N | N | Y | 6 | 12 | 1 |
| 9 | Discount rate stated & justified | N | N | N | N | N | N | Y | Y | Y | Y | N | Y | N | N | N | N | N | N | Y | 6 | 13 | 0 |
| 10 | Outcome measures stated & reference described | Y | P | P | P | P | P | P | Y | N | P | P | P | P | P | P | N | P | P | 2 | 2 | 15 |
| 11a (Single study) | Study described & why this is sufficient for effectiveness data | N | P | P | P | P | P | P | P | P | P | P | P | P | P | P | P | P | P | 0 | 1 | 14 |
| 11b (Model) | Methods for identification & synthesis described | Y | | | | | | | | | | | | | | | | | | | | 5 | 0 | 0 |
| 12 | Pop/methods for preference elicitation (if applicable) | Y | | | | | | | | | | | | | | | | | | | | 2 | 0 | 0 |
| 13a (Single study) | Methods for resource use & unit costs & adjustments | Y | N | Y | Y | Y | Y | Y | Y | Y | P | P | Y | P | Y | Y | Y | Y | Y | 11 | 2 | 3 |
| 13b (Model) | Methods/data sources for resource use & unit costs | Y | | | | | | | | | | | | | | | | | | | | 5 | 0 | 0 |
| 14 | Report dates of currency & methods for adjusting if appropriate | Y | Y | Y | Y | Y | Y | Y | Y | Y | N | Y | P | Y | Y | N | P | Y | Y | 15 | 2 | 2 |
| 15 | Model choice: describe & justify DA model choice, show model fig | Y | | | | | | | | | | | | | | | | | | | | 2 | 0 | 3 |

(Continued)
| Checklist | van Bedingen et al. | Barlow et al. | Bhavnani et al. | Caldwell et al. | Dietrich et al. | Drummond et al. | Edwards et al. | Foy et al. | Gna et al. | Hasali et al. | Kortz et al. | Lee et al. | Lloyd et al. | Martin et al. | Paladino et al. | van Werkhoven et al. | No. of Yes | No. of No | Partial |
|-----------|---------------------|--------------|----------------|----------------|----------------|----------------|----------------|-----------|-----------|---------------|-------------|-----------|-------------|---------------|----------------|-------------------------|-----------|----------|--------|
| 16 | Detail structural/other assumptions of DA model | N | | | | | Y | N | N | P | | | | | | | | 1 | 3 | 1 |
| 17 | Describe analytic methods incl skewed/missing data, extrapolation, pooling, model validation, uncertainty | N | N | N | N | N | N | N | N | N | N | N | P | N | N | Y | | 2 | 16 | 1 |
| Results | | | | | | | | | | | | | | | | | | | | | | |
| 18 | Report values, ranges for all params & (if applicable) prob dni (or reasons for dni) | N | Y | Y | N | Y | Y | Y | Y | Y | Y | Y | Y | P | P | P | Y | N | Y | P | 11 | 4 | 4 |
| 19 | Report each main cost category & outcomes for each option & mean diff and ICER (if applicable) | P | Y | Y | N | Y | Y | Y | N | P | P | P | N | Y | N | P | P | P | N | 6 | 6 | 7 |
| 20a (Single study) | Describe impact of simplifying uncertainty for dC, dE & ICER and impact of assumptions | N | N | N | N | N | N | N | Y | N | N | N | Y | P | N | P | P | P | 2 | 9 | 3 |
| 20b (Model) | Describe impact on results of uncertainty in params & assumptions | Y | | | | | | | | | | | | Y | N | Y | Y | | | 4 | 1 | 0 |
| 21 | (If applicable) Describe variation by subgrps or other variability in results not reducible by more info | Y | N | N | N | N | N | N | N | Y | N | N | N | Y | N | N | N | N | N | 4 | 15 | 0 |
| Discussion | | | | | | | | | | | | | | | | | | | | | | |
| 22 | Summarize key findings & say how support concl. Give lims, generally & how fits literature | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | 19 | 0 | 0 |
| Other | | | | | | | | | | | | | | | | | | | | | | |
| 23 | Study funding, role of funder, other non-$$ support noted | N | Y | N | N | N | N | N | Y | Y | N | Y | Y | Y | Y | Y | Y | Y | Y | 12 | 7 | 0 |
| 24 | Describe CoI as per jnl policy | N | Y | N | N | N | N | N | N | Y | N | Y | Y | Y | Y | Y | Y | Y | Y | N | N | Y | 10 | 9 | 0 |
| Score | 13.5 | 14.5 | 11.5 | 8.5 | 10.0 | 13.5 | 16.0 | 20.5 | 12.0 | 15.0 | 10.5 | 18.0 | 11.0 | 16.0 | 14.0 | 13.5 | 8.0 | 12.0 | 15.5 |
| Percentage | 61.4 | 69.0 | 54.8 | 49.5 | 47.6 | 61.4 | 76.2 | 85.4 | 57.1 | 65.2 | 50.0 | 75.0 | 52.4 | 76.2 | 60.9 | 64.3 | 38.1 | 57.1 | 73.8 |

Note: A score for '1' symbolized as 'Y' with appropriate reporting of the checklist, a score of 0.5 symbolized as 'P' that partially met the criterion, a score of 0 symbolized as 'N' if not reported at all.

https://doi.org/10.1371/journal.pone.0224170.t003
found that the newer antibiotics and/or interventions used for the management of pneumonia-exemplified value for money either in terms of cost-effectiveness against locally-relevant thresholds or by being cost-saving. Despite similarities in reported outcomes across studies, differences exist in assumptions, costs, currency and types of drugs used. These methodological challenges for comparison across studies are common in reviews of economic evidence [17]. This variation acts as barrier for other researchers as there is no clear consensus on what for components to include in cost and cost-effectiveness analysis. Comparing results across studies of different methodological approaches can highlight the importance of certain evaluation choices. For example, studies those included treatment costs for the side effects of drugs [31,32] reported a different cost profile than those that excluded these cost components. Due largely to the short time horizon of studies, most of the studies reviewed here did not consider the costs and effects of long-term follow up of drug treatment, which might cause over- or under-estimation of the drug costs compared to a longer time horizon.

In this review, most studies adopted a health system or hospital perspective for evaluation, while only two studies presented a broader societal perspective [27,28]. This is somewhat different to other reviews of economic evaluations, which have found societal perspective to be more common in other clinical areas, such as mental health [16].

Few studies described costs in detail by incorporating drug preparation costs, administration costs, costs of side effects, diagnostic tests costs, hospital stay and other relevant costs [25,32,33,36,38,39]. Although study/treatment duration of under one year meant that

![Fig 3. CHEERS score and the trend based on publication years.](https://doi.org/10.1371/journal.pone.0224170.g003)
discounting was not appropriate in many of the included studies, eight studies did not mention the study duration thus it could not be justified whether the discounting was applicable or not. It is encouraging that sensitivity analysis was performed by most of the studies using different parameters. Robust results were shown by six studies where mortality estimates, LoS, cost per day, and drug resistance were presented as the most sensitive parameters [27,32,34,37,38,40].

The difference in reported results between model-based and trial-based studies found here is similar to findings by Alouki and colleagues in a review of economic evidence for diabetes prevention, which suggests that there is a tendency of over-estimation in model-based studies [45]. Short study duration (often less than 30 days) and small sample size could influence the statistical significance of outcome and/or cost differences in trial-based studies, although this was not clearly the case, with several short-duration and small studies reporting significant results. Differences across studies in inclusion of cost items and valuation may also have influence on non-significant findings.

This study examined the quality of reporting in the existing economic evidence using the CHEERS checklist and found lack of compliance for many of the specified criteria within the checklist. This is similar to previous reviews of reporting quality of economic evaluation in other clinical areas [17,46].

The studies included in this review report outcome and cost data based largely on developed countries with aged people. This restricts the applicability of findings for LMIC country contexts, where children are the main vulnerable group for both morbidity and mortality due to pneumonia. The lack of information on households’ perspective on costs and outcomes suggests that incorporating a broader societal perspective and more diverse regional findings including both high and LMIC countries would support more rigorous, robust and useful comparative economic analysis.

**Strength and limitations**

Key strengths of this review include the use of pre-specified systematic review methods, systematic search applied to multiple relevant databases with no restriction on publication year, and quality appraisal using the widely-accepted CHEERS tool. The review included economic evaluation studies based on a range of clinical study designs, including RCT, model-based analysis, pre-post evaluation and case report or record review studies. Despite these strengths, the study has some limitations. Firstly, difference in unit costs of the studies and assortment of outcomes preventing any quantitative pooling of results and therefore we were unable to conduct meta-analysis or present results in a single cost-effectiveness plane. Secondly, the review is limited to literature published only in English thus might not capture all relevant articles. A number of studies were excluded on the basis of language and it is possible that inclusion of these studies may have provided different economic results to those reported above. Thirdly, while multiple databases were included, searching with specific databases may cause omission of some potential articles. Finally, no attempt was made to contact the authors of the selected articles or others in the field to explore any unreported information, thereby some extent of reporting bias cannot be ignored.

**Conclusions**

Comparative effectiveness with associated costs of different health care interventions for pneumonia management offers valuable insights of the cost-effectiveness of available health services that can inform policy and practice. Our review of the existing economic evidence for pneumonia management strategies demonstrates the various approaches to evaluation and study
designs for economic analysis in this area. The review identified potential inventions for management of pneumonia that could be cost-effective if implemented, although mostly concentrated on comparison of different antimicrobials at a health service level rather than offering innovative management strategies to improve overall societal costs and outcomes. The current evidence is largely based on high income countries and does not address the efficiency or feasibility of interventions in resource poor settings. Reporting quality varied, with much improvement to be made in the reporting of economic analysis in the literature.

Supporting information

S1 File. Search strategy and search results for conducting systematic review of economic evaluation of management strategies of pneumonia.
(DOCX)

S2 File. All titles found from systematic search from selected databases.
(XLSX)

S3 File. PRISMA 2009 checklist.
(DOC)

Acknowledgments

icddr,b is thankful to the Governments of Australia, Bangladesh, Canada, Sweden and the UK for providing core/unrestricted support. MS is supported by Deakin University Postgraduate Research Scholarship (DUPRS) provided by Deakin University, Australia. The authors thank colleagues at Deakin Health Economics for providing generous suggestions to improve the manuscript. Authors are also thankful to Deakin University Librarian Rachel West in designing search strategies and for selecting relevant databases.

Author Contributions

Conceptualization: Marufa Sultana, Lisa Gold.
Data curation: Marufa Sultana, Nausad Ali, Raisul Akram, Lisa Gold.
Formal analysis: Marufa Sultana, Abdur Razzaque Sarker, Nausad Ali, Raisul Akram, Lisa Gold.
Investigation: Nausad Ali, Raisul Akram.
Methodology: Marufa Sultana, Abdur Razzaque Sarker, Lisa Gold.
Supervision: Lisa Gold.
Validation: Abdur Razzaque Sarker, Lisa Gold.
Visualization: Raisul Akram, Lisa Gold.
Writing – original draft: Marufa Sultana.
Writing – review & editing: Abdur Razzaque Sarker, Nausad Ali, Raisul Akram, Lisa Gold.

References

1. Prina E, Ranzani OT, Torres A. Community-acquired pneumonia. Lancet. 2015; 386: 1097–1108. https://doi.org/10.1016/S0140-6736(15)60793-4 PMID: 26277247
2. Gutiérrez F, Masiá M, Mirete C, Soldán B, Carlos Rodríguez J, Padilla S, et al. The influence of age and gender on the population-based incidence of community-acquired pneumonia caused by different microbial pathogens. J Infect. 2006; 53: 166–174. https://doi.org/10.1016/j.jinf.2005.11.006 PMID: 16375972

3. Arnold FW, Wiemken TL, Peyrani P, Ramirez JA, Brock GN. Mortality differences among hospitalized patients with community-acquired pneumonia in three world regions: Results from the Community-Acquired Pneumonia Organization (CAPO) International Cohort Study. Respir Med. 2013; 107: 1101–1111. https://doi.org/10.1016/j.rmed.2013.04.003 PMID: 23660396

4. Murray CJL, Barber RM, Foreman KJ, Ozgoren AA, Abd-Allah F, Abera SF, et al. Global, national, and regional disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990–2013: Quantifying the epidemiological transition. Lancet. 2015; 386: 2145–2191. https://doi.org/10.1016/S0140-6736(15)61340-X PMID: 26321621

5. Ayieko P, Akumu AO, Griffiths UK, English M. The economic burden of inpatient paediatric care in Kenya: Household and provider costs for treatment of pneumonia, malaria and meningitis. Cost Eff Resour Alloc. 2009; 7: 1–13. https://doi.org/10.1186/1478-7547-7-1 PMID: 19845964

6. Madsen HO, Hanehej M, Das AR, Moses PD, Rose W, Puliyel M, et al. Costing of severe pneumonia in hospitalized infants and children aged 2–36 months, at a secondary and tertiary level hospital of a not-for-profit organization. Trop Med Int Heal. 2009; 14: 1315–1322. https://doi.org/10.1111/j.1365-3156.2009.02374.x PMID: 19719464

7. Saha S, Hasan M, Kim L, Farrar JL, Hossain B, Islam M, et al. Epidemiology and risk factors for pneumonia severity and mortality in Bangladeshi children <5 years of age before 10-valent pneumococcal conjugate vaccine introduction. BMC Public Health. 2016; 16: 1–12. https://doi.org/10.1186/s12889-015-2639-8 PMID: 26728978

8. Lim WS, Baudouin SV, George RC, Hill AT, Levy ML, Woodhead MA, Pneumonia Guidelines Committee of the BTS Standards of Care Committee. 2009. BTS guidelines for the management of community-acquired pneumonia in adults: update 2009. Thorax. 2009; 64: (Suppl 3):iii1–iii55. http://dx.doi.org/10.1136/thx.2009.121434.

9. Madhi SA, Levine OS, Hajjeh R, Mansoor OD, Cherian T. Vaccines to prevent pneumonia and improve child survival. Bull World Health Organ. 2008; 86: 365–372. https://doi.org/10.2471/BLT.07.044503 PMID: 18545739

10. Saha S, Hasan M, Kim L, Farrar JL, Hossain B, Islam M, et al. Clinical and economic burden of community-acquired pneumonia amongst adults in the Asia-Pacific region. Int J Antimicrob Agents. 2011; 38: 108–117. https://doi.org/10.1016/j.ijantimicag.2011.02.017 PMID: 21683553

11. WHO. Pocket Book of Hospital Care for Children: Guidelines for the Management of Common Childhood Illnesses [Internet]. Guidelines for the management of common illnesses. Geneva, Switzerland; 2013. http://dx.doi.org/10.1016/j.cardfail.2011.02.010

12. Mihalopoulos C, Chatterton ML. Economic evaluations of interventions designed to prevent mental disorders: A systematic review. Early Interv Psychiatry. 2015; 9: 85–92. https://doi.org/10.1111/eip.12156 PMID: 24962626

13. Hope SF, Webster J, Trieu K, Pillay A, Jeremia M, Bell C, et al. A systematic review of economic evaluations of population-based sodium reduction interventions. PLoS One. 2017; 12: 1–22. https://doi.org/10.1371/journal.pone.0173600 PMID: 28355231
20. Chisholm D, Evans DB. Economic evaluation in health: saving money or improving care? J Med Econ. 2007; 10: 325–337. https://doi.org/10.3111/13696990701605235

21. Mohr D, Liberati A, Tetzlaff J, Altman DG, Altman D, Antes G, et al. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med. 2009; 6. https://doi.org/10.1371/journal.pmed.1000097 PMID: 19621072

22. Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions version 5.1.0: updated February 2011. The Cochrane Collaboration; 2011; Available: http://www.cochrane-handbook.org

23. Huseinä D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al. Consolidated health economic evaluation reporting standards (CHEERS)-explanation and elaboration: A report of the ISPOR health economic evaluation publication guidelines good reporting practices task force. Value Heal. 2013; 16: 231–250. https://doi.org/10.1016/j.vheal.2013.02.002 PMID: 23538175

24. Palfreyman SJ, Stone PW. A systematic review of economic evaluations assessing interventions aimed at preventing or treating pressure ulcers. Int J Nurs Stud. 2015; 52: 769–788. https://doi.org/10.1016/j.ijnurstu.2014.06.004 PMID: 25012958

25. Hasali MAA, Ibrahim MIM, Sulaiman SAS, Ahmad Z, Hasali JBA. A clinical and economic study of community-acquired pneumonia between single versus combination therapy. Pharm World Sci. 2005; 27: 249–53. https://doi.org/10.11007/s11096-004-7039-6 PMID: 16096896

26. Kortz TB, Herzl B, Marseille E, Kahn JG. Bubble continuous positive airway pressure in the treatment of severe paediatric pneumonia in Malawi: A cost-effectiveness analysis. BMJ Open. 2017; 7. https://doi.org/10.1136/bmjopen-2016-015344 PMID: 28698327

27. Samsa GP, Matchar DB, Harnett J, Wilson J. A cost-minimization analysis comparing azithromycin-based and levofloxacin-based protocols for the treatment of patients hospitalized with community-acquired pneumonia: Results from the CAP-IN trial. Chest. 2005; 128: 3246–3254. https://doi.org/10.1378/chest.128.5.3246 PMID: 16304269

28. van Werkhoven CH, Postma DF, Mangen M-JJ, Oosterheert JJ, Bonten MJM. Cost-effectiveness of antibiotic treatment strategies for community-acquired pneumonia: results from a cluster randomized cross-over trial. BMC Infect Dis. 2017; 17: 52. https://doi.org/10.1186/s12879-016-2179-6 PMID: 28068956

29. Van Barlingen HJJ, Nuijten MJC, Volmer T, Sanderson DJ, Lacey LF. Model to evaluate the cost-effectiveness of different antibiotics in the management of acute bacterial exacerbations of chronic bronchitis in Germany. J Med Econ. 1998; 1: 201–218. https://doi.org/10.3111/199801201218

30. Barlow G, Nathwani D, Williams F, Ogston S, Winter J, Jones M, et al. Reducing door-to-antibiotic time in community-acquired pneumonia: Controlled before-and-after evaluation and cost-effectiveness analysis. Thorax. 2007; 62: 67–74. https://doi.org/10.1136/thx.2005.056689 PMID: 16928714

31. Dietrich ES, Joseph U, Vogel E, Howaldt S, Kullmann K-H, Frank EDD U.. Cost-Effec tiveness of Ceftriaxone 1 g vs Second-Generation Cephalosporins in the Treatment of Pneumonia in General Medical Wards in Germany. Infection. 1999; 16: 74–80.

32. Dresser LD, Niederman MS, Paladino JA. Cost-effectiveness of gatifloxacin vs ceftriaxone with a macrolide for the treatment of community-acquired pneumonia. Chest. 2001; 119: 1439–1448. https://doi.org/10.1378/chest.119.5.1439 PMID: 11348951

33. Bhavani SM, Ambrose PG. Cost-effectiveness of oral gemifloxacin versus intravenous ceftriaxone followed by oral cefuroxime with/without a macrolide for the treatment of hospitalized patients with community-acquired pneumonia. Diagn Microbiol Infect Dis. 2008; 60: 59–64. https://doi.org/10.1016/j.diagmicrobio.2007.07.006 PMID: 17889491

34. Caldwell JW, Singh S, Johnson RH. Clinical and economic evaluation of subsequent infection following intravenous ciprofloxacin or imipenem therapy in hospitalized patients with severe pneumonia. J Antimicrob Chemother. 1999; 43: 129–134. PMID: 10225583

35. Bahadari K, Quon BS, Doyle-Waters MM, Marra C, Fitzgerald JM. A systematic review of economic evaluations of therapy in asthma. J Asthma Allergy. 2010; 3: 33–42. PMID: 21437038

36. Drummond MF, Becker DL, Hux M, Chancellor JVM, Duprat-Lomon I, Kubin R, et al. An economic evaluation of sequential IV/po moxifloxacin therapy compared to IV/po co-amoxiclav with or without clarithromycin in the treatment of community-acquired pneumonia. Chest. 2003; 124: 526–535. https://doi.org/10.1378/chest.124.2.526 PMID: 12907538

37. Lloyd A, Holman A, Evers T. A cost-minimisation analysis comparing moxifloxacin with levofloxacin plus ceftriaxone for the treatment of patients with community-acquired pneumonia in Germany: results from the MOTIV trial. Curr Med Res Opin. 2008; 24: 1279–1284. https://doi.org/10.1185/030079908X280400 PMID: 18358083

38. Paladino JA, Gudgel LD, Forrest A, Niederman MS. Cost-effectiveness of IV-to-oral switch therapy: Azithromycin vs cefuroxime with or without erythromycin for the treatment of community-acquired pneumonia. Chest. 2002; 122: 1271–1279. https://doi.org/10.1378/chest.122.4.1271 PMID: 12377852
39. Edwards SJ, Wordsworth S, Clarke MJ. Treating pneumonia in critical care in the United Kingdom following failure of initial antibiotic: a cost-utility analysis comparing meropenem with piperacillin / tazobactam. Eur J Health Econ. 2012; 181–192. https://doi.org/10.1007/s10198-011-0296-0 PMID: 21243514

40. Frei BCR, Burgess DS. Cost-effectiveness of 4 empiric antimicrobial regimens in patients with community-acquired pneumonia. 2005;

41. Grau S, Lozano V, Valladares A, Cavanillas R, Xie Y, Nocea G. Antibiotic expected effectiveness and cost under real life microbiology: Evaluation of ertapenem and ceftriaxone in the treatment of community-acquired pneumonia for elderly patients in Spain. Clin Outcomes Res. 2014; 6: 83–92. https://doi.org/10.2147/ceor.s55265 PMID: 24611019

42. Martin M, Moore L, Quilici S, Decramer M, Simoens S. A cost-effectiveness analysis of antimicrobial treatment of community-acquired pneumonia taking into account resistance in Belgium. Curr Med Res Opin. 2008; 24: 737–751. https://doi.org/10.1185/030079908X273336 PMID: 18230196

43. Rittenhouse BE, Stinnett AA, Dulisse B, Henke CJ, Potter L, Parasuraman B, et al. An economic evaluation of levofloxacin versus cefuroxime axetil in the outpatient treatment of adults with community-acquired pneumonia. Am J Manag Care. 2000; 6: 381–389. PMID: 10977438

44. Lee KKC, Wan MHS, Fan BSK, Chau MWY, Lee VWY. A cost-minimisation analysis comparing different antibiotic regimens used in treating all-cause bacterial pneumonia in Hong Kong. J Med Econ. 2009; 12: 46–55. https://doi.org/10.3111/13696990902840227 PMID: 19450064

45. Alouki K, Delisle H, Bermudez-Tamayo C, Johri M. Lifestyle interventions to prevent type 2 diabetes: a systematic review of economic evaluation studies. J Diabetes Res. 2016; 2016: 2159890. https://doi.org/10.1155/2016/2159890 PMID: 26885527

46. Steel A, Sundberg T, Reid R, Ward L, Bishop FL, Leach M, et al. Osteopathic manipulative treatment: A systematic review and critical appraisal of comparative effectiveness and health economics research. Musculoskelet Sci Pract. 2017; 27: 165–175. https://doi.org/10.1016/j.math.2016.10.067 PMID: 27852531